REAL WORLD HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH PANCREATIC CANCERIN THE BRAZILIAN PRIVATE MARKET
Author(s)
Joao Paulo Dos Reis Neto, PhD, MD1, JULIANA BUSCH, MD2;
1Diretor-Presidente da Capesesp, ceo, Rio de Janeiro, Brazil, 2CAPESESP, Rio de Janeiro, Brazil
1Diretor-Presidente da Capesesp, ceo, Rio de Janeiro, Brazil, 2CAPESESP, Rio de Janeiro, Brazil
OBJECTIVES: Pancreatic cancer (PC), although relatively uncommon, represents a high-impact disease due to its aggressive course, high mortality rate and intensive resource demands. This study aims to evaluate the healthcare resource utilization (HCRU) and costs with PC in a private health care plan.
METHODS: Retrospective analysis using administrative data (Jan/2019-Dec/2024) to evaluate adult patients with ICD-10 C25. Demographics, treatments, HCRU (visits, emergency department (ER), tests, therapies and hospitalizations) and costs were analyzed. Kaplan-Meier curves were used to estimate the survival rates. Chi-square, Fisher’s and Student’s t-tests for categorical/continuous variables. Statistical significance: p<0.05.
RESULTS: Of 54,829 beneficiaries (57 years; 60,4% females) the PC prevalence rate was 167/100,000 (72 years; 52% female). Overall, 32.5% of the patients had resectable disease at diagnosis and were treated with surgery alone. The remaining 67.5% had advanced disease and were treated with: chemotherapy (79.3%), only palliative care (11.6%), and immunotherapy (9,1%). Only 39.1% of patients remained eligible for multiple treatment lines. Most common treatment sequences: 47,8% fluorouracil-based followed by gemcitabine-based, 39,1% gemcitabine-based and 16,1% others. Annual cost per-patient: USD 20,195 (40.1% hospitalizations and 28.7% chemotherapy). Annual rates of procedures average per-patient: visits 7.8, ER 3.0, tests 113.3, therapies 6.1 and hospitalizations 1.7. Five-year survival rate: 21.4% late-stage diagnosis and 51.4% resectable cases (p<0.05).
CONCLUSIONS: Most cases were diagnosed at an advanced stage, underscoring persistent challenges in early detection. Despite prevalent chemotherapy use, only 39.1% of patients remained fit enough to receive multiple treatment lines, suggesting rapid clinical deterioration and highlighting unmet needs for more effective and tolerable therapies. Treatment patterns showed variability in sequencing. HCRU and costs were considerable. Late-stage diagnosis is linked to poorer survival rates, highlighting the critical need for earlier detection and therapies that can effectively penetrate and overcome the pancreatic stromal barrier.
METHODS: Retrospective analysis using administrative data (Jan/2019-Dec/2024) to evaluate adult patients with ICD-10 C25. Demographics, treatments, HCRU (visits, emergency department (ER), tests, therapies and hospitalizations) and costs were analyzed. Kaplan-Meier curves were used to estimate the survival rates. Chi-square, Fisher’s and Student’s t-tests for categorical/continuous variables. Statistical significance: p<0.05.
RESULTS: Of 54,829 beneficiaries (57 years; 60,4% females) the PC prevalence rate was 167/100,000 (72 years; 52% female). Overall, 32.5% of the patients had resectable disease at diagnosis and were treated with surgery alone. The remaining 67.5% had advanced disease and were treated with: chemotherapy (79.3%), only palliative care (11.6%), and immunotherapy (9,1%). Only 39.1% of patients remained eligible for multiple treatment lines. Most common treatment sequences: 47,8% fluorouracil-based followed by gemcitabine-based, 39,1% gemcitabine-based and 16,1% others. Annual cost per-patient: USD 20,195 (40.1% hospitalizations and 28.7% chemotherapy). Annual rates of procedures average per-patient: visits 7.8, ER 3.0, tests 113.3, therapies 6.1 and hospitalizations 1.7. Five-year survival rate: 21.4% late-stage diagnosis and 51.4% resectable cases (p<0.05).
CONCLUSIONS: Most cases were diagnosed at an advanced stage, underscoring persistent challenges in early detection. Despite prevalent chemotherapy use, only 39.1% of patients remained fit enough to receive multiple treatment lines, suggesting rapid clinical deterioration and highlighting unmet needs for more effective and tolerable therapies. Treatment patterns showed variability in sequencing. HCRU and costs were considerable. Late-stage diagnosis is linked to poorer survival rates, highlighting the critical need for earlier detection and therapies that can effectively penetrate and overcome the pancreatic stromal barrier.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD156
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology